HK1199893A1 - Use of chemically modified heparin derivates in sickle cell disease - Google Patents

Use of chemically modified heparin derivates in sickle cell disease

Info

Publication number
HK1199893A1
HK1199893A1 HK15100356.1A HK15100356A HK1199893A1 HK 1199893 A1 HK1199893 A1 HK 1199893A1 HK 15100356 A HK15100356 A HK 15100356A HK 1199893 A1 HK1199893 A1 HK 1199893A1
Authority
HK
Hong Kong
Prior art keywords
chemically modified
sickle cell
cell disease
modified heparin
derivates
Prior art date
Application number
HK15100356.1A
Other languages
English (en)
Chinese (zh)
Inventor
Hans-Peter Ekre
Anna Leitgeb
Mats Wahlgren
Dagmar Pikas
Original Assignee
Dilaforette Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dilaforette Ab filed Critical Dilaforette Ab
Publication of HK1199893A1 publication Critical patent/HK1199893A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727Heparin; Heparan
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078Degradation products
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15100356.1A 2011-12-19 2015-01-13 Use of chemically modified heparin derivates in sickle cell disease HK1199893A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/SE2011/051538 WO2013095215A1 (en) 2011-12-19 2011-12-19 Low anticoagulant heparins
PCT/SE2012/051429 WO2013095277A1 (en) 2011-12-19 2012-12-19 Use of chemically modified heparin derivates in sickle cell disease

Publications (1)

Publication Number Publication Date
HK1199893A1 true HK1199893A1 (en) 2015-07-24

Family

ID=48668926

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15100356.1A HK1199893A1 (en) 2011-12-19 2015-01-13 Use of chemically modified heparin derivates in sickle cell disease
HK15100897.7A HK1200471A1 (en) 2011-12-19 2015-01-27 Low anticoagulant heparins

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15100897.7A HK1200471A1 (en) 2011-12-19 2015-01-27 Low anticoagulant heparins

Country Status (26)

Country Link
US (2) US9480702B2 (hr)
EP (2) EP2794667B1 (hr)
JP (2) JP6703806B2 (hr)
CN (1) CN104053675B (hr)
AU (1) AU2012354226B2 (hr)
BR (1) BR112014014673B1 (hr)
CA (2) CA2856477C (hr)
CY (2) CY1120197T1 (hr)
DK (2) DK2794666T3 (hr)
ES (2) ES2668273T3 (hr)
HK (2) HK1199893A1 (hr)
HR (2) HRP20180726T1 (hr)
HU (2) HUE037554T2 (hr)
IL (1) IL232903A (hr)
IN (1) IN2014MN01056A (hr)
MX (1) MX358439B (hr)
MY (1) MY170069A (hr)
NO (2) NO2794666T3 (hr)
PH (1) PH12014501387B1 (hr)
PL (2) PL2794667T3 (hr)
PT (2) PT2794667T (hr)
RS (2) RS57213B1 (hr)
SI (2) SI2794666T1 (hr)
TN (2) TN2014000236A1 (hr)
WO (3) WO2013095215A1 (hr)
ZA (1) ZA201403654B (hr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013095215A1 (en) 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
PL2794665T3 (pl) 2011-12-19 2018-04-30 Dilafor Ab Niewykazujące działania przeciwkrzepliwego glikozaminoglikany zawierające powtarzające się jednostki disacharydowe i ich zastosowanie medyczne
GB2515315A (en) 2013-06-19 2014-12-24 Dilafor Ab New Processes
EP2965764A1 (en) * 2014-07-11 2016-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating vaso-occlusive crisis
ES2749076T3 (es) * 2014-04-30 2020-03-19 Inst Nat Sante Rech Med DNasa para uso en el tratamiento de crisis vaso-oclusivas
CN105504097B (zh) * 2015-12-30 2018-07-03 深圳市海普瑞药业集团股份有限公司 一种硫酸化肝素寡糖及其制备方法和应用
CN108424474B (zh) * 2017-02-15 2023-07-25 清华大学 去抗凝肝素衍生物及其用于炎症性肠病的治疗
US20210052779A1 (en) * 2018-04-13 2021-02-25 University Of Virginia Patent Foundation Compositions and methods for preparing and using non-immunogenic fast annealing microporous annealed particle hydrogels
CN109481692A (zh) * 2018-11-30 2019-03-19 东南大学 一种青蒿琥酯肝素衍生物及其药物组合物和应用
WO2023239711A1 (en) * 2022-06-06 2023-12-14 Ihp Therapeutics Inc. Chemically modified heparin
CN115448994B (zh) * 2022-09-28 2023-08-01 山东大学 一种可中和抗凝低分子量肝素及其制备方法和应用
WO2024072942A2 (en) * 2022-09-29 2024-04-04 Adora Animal Health Corporation Skin penetrating formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions
GB2625581A (en) * 2022-12-21 2024-06-26 Modus Therapeutics Ab New medical use

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1136620A (en) 1979-01-08 1982-11-30 Ulf P.F. Lindahl Heparin fragments having selective anticoagulation activity
FR2614026B1 (fr) 1987-04-16 1992-04-17 Sanofi Sa Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
ES2054975T3 (es) * 1988-10-07 1994-08-16 Hoechst Ag Composiciones antimalaricas que emplean quinidina, artemisinina y sus derivados.
SE9002550D0 (sv) 1990-08-01 1990-08-01 Kabivitrum Ab Heparinfragment
SE9003181D0 (sv) 1990-10-04 1990-10-04 Kabivitrum Ab Use of heparin fraction
US5280016A (en) * 1991-03-29 1994-01-18 Glycomed Incorporated Non-anticoagulant heparin derivatives
US5250519A (en) * 1991-03-29 1993-10-05 Glycomed Incorporated Non-anticoagulant heparin derivatives
JPH0532703A (ja) * 1991-07-26 1993-02-09 Terumo Corp 低分子量ヘパリン誘導体の製造法
WO1994008595A1 (en) 1992-10-13 1994-04-28 Virginia Commonwealth University Use of non-anticoagulant heparin for treating ischemia/reperfusion injury
US5527785A (en) * 1993-05-14 1996-06-18 The Regents Of The University Of California Selectin receptor modulating compositions
DE69623840D1 (de) * 1995-03-31 2002-10-31 Hamilton Civic Hospitals Res Zusammensetzung zur Hemmung der Thromboseentstehung
US5993810A (en) 1996-03-15 1999-11-30 Lebovitz; Shamir Israel Method of softening or ripening the cervix of a female mammal using collagenase
US5767269A (en) 1996-10-01 1998-06-16 Hamilton Civic Hospitals Research Development Inc. Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
WO1998016559A1 (fr) 1996-10-15 1998-04-23 Toray Industries, Inc. Agent de maturation des canaux cervicaux
GB9711443D0 (en) 1997-06-03 1997-07-30 Leo Pharm Prod Ltd Chemical suppositions
CA2310422A1 (en) * 1997-11-20 1999-06-03 Ikuo Yamashina Low-molecular heparin modification and remedy for skin ulcer
US6596705B1 (en) 1998-02-09 2003-07-22 The Regents Of The University Of California Inhibition of L-selectin and P-selection mediated binding using heparin
US6498246B1 (en) 1998-02-26 2002-12-24 Seikagaku Corporation Glycosaminoglycan derivatives and processes for preparing same
US6028061A (en) * 1998-06-18 2000-02-22 Children's Medical Center Corp Angiogenesis inhibitors and use thereof
EP1022289B1 (en) * 1998-07-31 2004-07-07 Seikagaku Corporation Novel glycosaminoglycan and drug compositions containing the same
MXPA02000142A (es) * 1999-06-30 2003-07-21 Hamilton Civic Hospitals Res Composiciones de heparina que inhiben los factores de coagulacion asociados con el coagulo.
JP4897991B2 (ja) * 1999-07-23 2012-03-14 ラボラトリオス ファルマセウティコス ロビ ソシエダッド アノニマ 超低分子量ヘパリン組成物
IT1316986B1 (it) 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
JP4585072B2 (ja) * 2000-02-29 2010-11-24 扶桑薬品工業株式会社 ヘパリン解重合法、解重合ヘパリン、その誘導体および医薬組成物
WO2002023190A2 (en) * 2000-09-12 2002-03-21 Massachusetts Institute Of Technology Methods and products related to low molecular weight heparin
SE521676C2 (sv) 2002-01-02 2003-11-25 Dilafor Ab Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
EP1542704A1 (en) 2002-04-18 2005-06-22 Stephen H. Embury Method and composition for preventing pain in sickle cell patients
US8071569B2 (en) * 2002-09-20 2011-12-06 Mousa Shaker A Oxidized heparin fractions and their use in inhibiting angiogenesis
EP1582531A1 (en) 2004-03-24 2005-10-05 Aventis Pharma S.A. Process for oxidizing unfractionated heparins and detecting presence or absence of glycoserine in heparin and heparin products
EP2258349B1 (en) * 2004-05-11 2014-07-16 Egalet Ltd. Swellable dosage form comprising gellan gum
US20060040896A1 (en) * 2004-08-18 2006-02-23 Paringenix, Inc. Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
US7741311B2 (en) * 2005-01-03 2010-06-22 Shaker Mousa Composition and method for treating occlusive vascular diseases, nerve regeneration, and wound healing
WO2007014155A2 (en) 2005-07-22 2007-02-01 Trf Pharma, Inc. Method for treating sickle cell disease and sickle cell disease sequelae
US20070021378A1 (en) * 2005-07-22 2007-01-25 The Regents Of The University Of California Heparin compositions and selectin inhibition
JP2009538386A (ja) * 2006-05-25 2009-11-05 モメンタ ファーマシューティカルズ インコーポレイテッド 低分子量ヘパリン組成物およびその使用
WO2009007224A1 (en) * 2007-07-10 2009-01-15 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Low molecular weight heparin derivatives having neuroprotective activity
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US8592393B2 (en) * 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
ES2567079T3 (es) * 2007-11-02 2016-04-19 Momenta Pharmaceuticals, Inc. Composiciones de polisacáridos que no son anticoagulantes
WO2009073184A1 (en) 2007-12-03 2009-06-11 Florida State University Research Foundation, Inc. Compositions for inducing labor and associated methods
KR101594552B1 (ko) * 2008-04-04 2016-02-17 유니버시티 오브 유타 리서치 파운데이션 알킬화된 반합성 글리코사미노글리코산 에테르 및 이의 제조 및 사용 방법
US20110206770A1 (en) * 2008-07-25 2011-08-25 Alphapharm Pty. Ltd. Atovaquone with a particle size diameter range (d90) of greater than 3 microns to about 10 microns
CA2758520A1 (en) * 2009-04-16 2010-10-21 Momenta Pharmaceuticals, Inc. Methods of assessing activity of a polysaccharide composition
WO2011000032A1 (en) * 2009-06-30 2011-01-06 Walter And Eliza Hall Institute Of Medical Research Sulfated polysaccharides having antiplasmodial activity and methods and products for identifying antiplasmodial activity
WO2013095215A1 (en) 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
PL2794665T3 (pl) 2011-12-19 2018-04-30 Dilafor Ab Niewykazujące działania przeciwkrzepliwego glikozaminoglikany zawierające powtarzające się jednostki disacharydowe i ich zastosowanie medyczne
MX2014011505A (es) 2012-03-26 2014-12-05 Dilafor Ab Terapias para inducir el parto.
SG11201406118QA (en) 2012-03-26 2014-11-27 Dilafor Ab Method for treatment of labor arrest

Also Published As

Publication number Publication date
TN2014000236A1 (en) 2015-09-30
AU2012354226B2 (en) 2017-01-12
PH12014501387A1 (en) 2014-09-22
EP2794666B1 (en) 2018-02-21
IL232903A0 (en) 2014-07-31
HRP20180725T1 (hr) 2018-06-29
US20150031638A1 (en) 2015-01-29
CY1120194T1 (el) 2018-12-12
IN2014MN01056A (hr) 2015-05-01
RS57213B1 (sr) 2018-07-31
RS57214B1 (sr) 2018-07-31
NO2794666T3 (hr) 2018-07-21
PL2794667T3 (pl) 2018-09-28
ES2668273T3 (es) 2018-05-17
WO2013095277A1 (en) 2013-06-27
HRP20180726T1 (hr) 2018-06-15
CA2856477C (en) 2017-06-27
SI2794667T1 (en) 2018-06-29
BR112014014673A2 (pt) 2017-06-13
JP2015500387A (ja) 2015-01-05
JP6703806B2 (ja) 2020-06-03
DK2794667T3 (en) 2018-04-23
IL232903A (en) 2017-02-28
WO2013095215A1 (en) 2013-06-27
EP2794667B1 (en) 2018-02-21
US9480702B2 (en) 2016-11-01
US20140364369A1 (en) 2014-12-11
PT2794666T (pt) 2018-05-09
SI2794666T1 (en) 2018-06-29
MX358439B (es) 2018-08-21
AU2012354226A1 (en) 2014-06-05
HUE037554T2 (hu) 2018-09-28
BR112014014673A8 (pt) 2017-07-04
CA2856477A1 (en) 2013-06-27
CA2856918C (en) 2017-07-04
EP2794666A4 (en) 2015-07-22
CN104053675B (zh) 2016-10-12
JP2018154848A (ja) 2018-10-04
CY1120197T1 (el) 2018-12-12
HUE037555T2 (hu) 2018-09-28
ZA201403654B (en) 2017-08-30
NZ625096A (en) 2016-07-29
US9480701B2 (en) 2016-11-01
MX2014006956A (es) 2014-10-17
BR112014014673B1 (pt) 2021-02-17
EP2794667A1 (en) 2014-10-29
CA2856918A1 (en) 2013-06-27
WO2013095276A1 (en) 2013-06-27
EP2794667A4 (en) 2015-07-22
DK2794666T3 (en) 2018-04-23
ES2669055T3 (es) 2018-05-23
NO2794667T3 (hr) 2018-07-21
TN2014000237A1 (en) 2015-09-30
MY170069A (en) 2019-07-03
PT2794667T (pt) 2018-05-16
PH12014501387B1 (en) 2014-09-22
PL2794666T3 (pl) 2018-08-31
CN104053675A (zh) 2014-09-17
HK1200471A1 (en) 2015-08-07
EP2794666A1 (en) 2014-10-29

Similar Documents

Publication Publication Date Title
HRP20180726T1 (hr) Upotreba derivata kemijski modificiranog heparina za bolest srpastih stanica
EP2768423A4 (en) OPHTHALMIC STRUCTURE
BR112013032559A2 (pt) cookie em camads saudável
EP2704231A4 (en) BATTERY UNIT
PL2701572T3 (pl) Zmywarka do naczyń z filtrem
EP2773262A4 (en) ASSESSMENT OF A CARDIAL STRUCTURE
EP2708159A4 (en) COMPUTER CHAIR
HK1203480A1 (en) Ophthalmic formulation
HK1211498A1 (en) Treatment of sickle cell disease and inflammatory conditions
GB2511220B (en) Critical capacitor built in test
EP2678339A4 (en) METHOD AND COMPOSITIONS FOR TREATING BETA THALASSEMIA AND SICKEN LAMINA
EP2790543A4 (en) SHOE TO BE USED DURING SPECIAL ACTIVITIES
HK1198587A1 (en) Isothiazolopyridine-2-carboxamides and their use as pharmaceuticals -2-
LT2794666T (lt) Chemiškai modifikuoto heparino darinių panaudojimas, esant pjautuvo pavidalo ląstelių anemijai
GB201115917D0 (en) Super high capacity battery
AU335230S (en) Sunglasses
AU335229S (en) Sunglasses
AU335228S (en) Sunglasses
AU335235S (en) Sunglasses
AU335233S (en) Sunglasses
AU335234S (en) Sunglasses
GB201108918D0 (en) Improvements in or relating to appliances or storage units
GB201108433D0 (en) Stratified b-trees
GB201104681D0 (en) Roles for chitinase-like proteins in disease states
GB201105921D0 (en) Improvements in or relating to storage

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20211218